Nkarta, Inc. (NKTX)

Market Cap	199.61M +52.5%
Revenue (ttm)	n/a
Net Income	-104.08M
EPS	-1.41
Shares Out	71.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,688,365
Open	2.470
Previous Close	2.420
Day's Range	2.455 - 2.815
52-Week Range	1.630 - 2.815
Beta	0.67
Analysts	Strong Buy
Price Target	11.33 (+304.64%)
Earnings Date	May 13, 2026

About NKTX

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The com...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 10, 2020
• Employees: 108
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTX
• Website: https://www.nkartatx.com

Analyst Summary

According to 4 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price target is $11.33, which is an increase of 304.64% from the latest price.

Price Target

$11.33

(304.64% upside)

Analyst Consensus: Strong Buy